La Jolla Pharmaceutical (LJPC) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 25, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	LA JOLLA PHARMACEUTICAL CO
Entity Central Index Key	0000920465
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Shell Company	false
Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		27,157,205

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 104,768	$ 172,604
Accounts receivable, net	1,417	1,381
Inventory, net	1,910	2,020
Prepaid expenses and other current assets	4,783	5,111
Total current assets	112,878	181,116
Property and equipment, net	19,523	22,267
Right-of-use lease asset	15,829
Restricted cash	909	909
Total assets	149,139	204,292
Current liabilities:
Accounts payable	5,338	8,572
Accrued expenses	9,351	8,485
Accrued payroll and related expenses	5,118	7,509
Lease liability, current portion	2,705
Deferred rent, current portion	0	1,370
Total current liabilities	22,512	25,936
Deferred rent, less current portion	0	13,609
Lease liability, less current portion	27,199
Deferred royalty obligation, net	124,366	124,323
Other noncurrent liabilities	10,233	4,503
Total liabilities	184,310	168,371
Shareholders’ (deficit) equity:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,147,387 and 26,259,254 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	3	3
Additional paid-in capital	973,018	950,258
Accumulated deficit	(1,012,098)	(920,983)
Total shareholders’ (deficit) equity	(35,171)	35,921
Total liabilities and shareholders’ (deficit) equity	149,139	204,292
Series C-1 Convertible Preferred Stock [Member]
Shareholders’ (deficit) equity:
Convertible preferred stock, value	3,906	3,906
Series F Convertible Preferred Stock [Member]
Shareholders’ (deficit) equity:
Convertible preferred stock, value	$ 0	$ 2,737

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	27,147,387	26,259,254
Common stock, shares outstanding (in shares)	27,147,387	26,259,254
Series C-1 Convertible Preferred Stock [Member]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	11,000	11,000
Preferred stock, shares issued (in shares)	3,906	3,906
Preferred stock, shares outstanding (in shares)	3,906	3,906
Preferred stock, liquidation	$ 3,906	$ 3,906
Series F Convertible Preferred Stock [Member]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000	10,000
Preferred stock, shares issued (in shares)	0	2,737
Preferred stock, shares outstanding (in shares)	0	2,737
Preferred stock, liquidation	$ 0	$ 2,737

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue
Net product sales	$ 5,706	$ 3,470	$ 15,804	$ 5,872
Total revenue	5,706	3,470	15,804	5,872
Operating expenses
Cost of product sales	554	256	1,605	443
Research and development	21,182	30,439	64,469	89,735
Selling, general and administrative	10,782	21,139	34,425	66,319
Total operating expenses	32,518	51,834	100,499	156,497
Loss from operations	(26,812)	(48,364)	(84,695)	(150,625)
Interest expense	(2,863)	(2,926)	(8,398)	(4,581)
Interest income	501	545	1,818	1,155
Total other expense, net	(2,362)	(2,381)	(6,580)	(3,426)
Net loss	$ (29,174)	$ (50,745)	$ (91,275)	$ (154,051)
Net loss per share, basic and diluted (usd per share)	$ (1.08)	$ (1.93)	$ (3.37)	$ (6.15)
Weighted-average common shares outstanding - basic and diluted (in shares)	27,135	26,226	27,093	25,055

Unaudited Consolidated Statemen

Unaudited Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock [Member]Series C-1 Convertible Preferred Stock [Member]	Preferred Stock [Member]Series F Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings
Beginning Balance (in shares) at Dec. 31, 2017		4	3	22,167
Beginning Balance at Dec. 31, 2017	$ 88,202	$ 3,906	$ 2,737	$ 2	$ 803,071	$ (721,514)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	9,402				9,402
Issuance of common stock for conversion of Series F Preferred Stock (in shares)				3,910
Issuance of common stock for conversion of Series F Preferred Stock	109,809			$ 1	109,808
Exercise of stock options for common stock (in shares)				77
Exercise of stock options for common stock	528				528
Net loss	(50,528)					(50,528)
Ending Balance (in shares) at Mar. 31, 2018		4	3	26,154
Ending Balance at Mar. 31, 2018	157,413	$ 3,906	$ 2,737	$ 3	922,809	(772,042)
Beginning Balance (in shares) at Dec. 31, 2017		4	3	22,167
Beginning Balance at Dec. 31, 2017	88,202	$ 3,906	$ 2,737	$ 2	803,071	(721,514)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(154,051)
Ending Balance (in shares) at Sep. 30, 2018		4	3	26,227
Ending Balance at Sep. 30, 2018	74,994	$ 3,906	$ 2,737	$ 3	943,913	(875,565)
Beginning Balance (in shares) at Mar. 31, 2018		4	3	26,154
Beginning Balance at Mar. 31, 2018	157,413	$ 3,906	$ 2,737	$ 3	922,809	(772,042)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	9,844				9,844
Exercise of stock options for common stock (in shares)				65
Exercise of stock options for common stock	1,188				1,188
Net loss	(52,778)					(52,778)
Ending Balance (in shares) at Jun. 30, 2018		4	3	26,219
Ending Balance at Jun. 30, 2018	115,667	$ 3,906	$ 2,737	$ 3	933,841	(824,820)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	9,880				9,880
Exercise of stock options for common stock (in shares)				8
Exercise of stock options for common stock	192				192
Net loss	(50,745)					(50,745)
Ending Balance (in shares) at Sep. 30, 2018		4	3	26,227
Ending Balance at Sep. 30, 2018	74,994	$ 3,906	$ 2,737	$ 3	943,913	(875,565)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASU 2018-07	0
Beginning Balance (in shares) at Dec. 31, 2018		4	3	26,259
Beginning Balance at Dec. 31, 2018	35,921	$ 3,906	$ 2,737	$ 3	950,258	(920,983)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,782				6,782
Issuance of common stock under ESPP (in shares)				52
Issuance of common stock under ESPP	283				283
Issuance of common stock for conversion of Series F Preferred Stock (in shares)			(3)	782
Issuance of common stock for conversion of Series F Preferred Stock			$ (2,737)		2,737
Net loss	(31,685)					(31,685)
Ending Balance (in shares) at Mar. 31, 2019		4	0	27,093
Ending Balance at Mar. 31, 2019	11,301	$ 3,906	$ 0	$ 3	959,900	(952,508)
Beginning Balance (in shares) at Dec. 31, 2018		4	3	26,259
Beginning Balance at Dec. 31, 2018	35,921	$ 3,906	$ 2,737	$ 3	950,258	(920,983)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(91,275)
Ending Balance (in shares) at Sep. 30, 2019		4	0	27,147
Ending Balance at Sep. 30, 2019	(35,171)	$ 3,906	$ 0	$ 3	973,018	(1,012,098)
Beginning Balance (in shares) at Mar. 31, 2019		4	0	27,093
Beginning Balance at Mar. 31, 2019	11,301	$ 3,906	$ 0	$ 3	959,900	(952,508)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,321				6,321
Issuance of common stock under ESPP (in shares)				32
Issuance of common stock under ESPP	201				201
Net loss	(30,416)					(30,416)
Ending Balance (in shares) at Jun. 30, 2019		4	0	27,125
Ending Balance at Jun. 30, 2019	(12,593)	$ 3,906	$ 0	$ 3	966,422	(982,924)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,419				6,419
Issuance of common stock under ESPP (in shares)				22
Issuance of common stock under ESPP	177				177
Net loss	(29,174)					(29,174)
Ending Balance (in shares) at Sep. 30, 2019		4	0	27,147
Ending Balance at Sep. 30, 2019	(35,171)	$ 3,906	$ 0	$ 3	$ 973,018	$ (1,012,098)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative-effect adjustment from adoption of ASU 2018-07	$ (160)

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities
Net loss	$ (91,275)	$ (154,051)
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense	19,522	29,126
Depreciation expense	3,408	3,245
Loss on disposal of equipment	15	236
Non-cash interest expense	6,971	4,421
Non-cash rent expense	969	0
Changes in operating assets and liabilities:
Accounts receivable, net	(36)	(1,537)
Inventory, net	110	(1,101)
Prepaid expenses and other current assets	328	(2,700)
Accounts payable	(3,234)	(4,914)
Accrued expenses	(332)	5,906
Accrued payroll and related expenses	(2,391)	(73)
Lease liability	(1,873)	0
Deferred rent	0	1,110
Net cash used for operating activities	(67,818)	(120,332)
Investing activities
Purchase of property and equipment	(679)	(2,252)
Net cash used for investing activities	(679)	(2,252)
Financing activities
Proceeds from the issuance of common stock under ESPP	661	0
Proceeds From Royalties Financing	0	124,289
Net proceeds from the issuance of common stock	0	109,809
Net proceeds from the exercise of stock options for common stock	0	1,908
Net cash provided by financing activities	661	236,006
Net (decrease) increase in cash and restricted cash	(67,836)	113,422
Cash and restricted cash at beginning of period	173,513	91,824
Cash and restricted cash at end of period	105,677	205,246
Supplemental disclosure of non-cash investing and financing activities:
Noncash Or Part Noncash Transaction, Conversion Of Preferred Stock, Common Stock	2,737	0
Initial recognition of right-of-use lease asset	16,798
Reconciliation of cash and restricted cash to the condensed consolidated balance sheets
Total cash and restricted cash	$ 173,513	$ 91,824

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of SEC Regulation S-X. Accordingly, they should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 , filed with the SEC on March 4, 2019 (the “Form 10-K”). The accompanying unaudited condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated balance sheet as of September 30, 2019 , the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 , the condensed consolidated statement of shareholders' (deficit) equity for the three and nine ended September 30, 2019 and the condensed consolidated statement of cash flows for the nine months ended September 30, 2019 . The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ equity or cash flows. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated balance sheet as of December 31, 2018 contained in the Form 10-K. Summary of Significant Accounting Policies During the nine months ended September 30, 2019 , there have been no changes to the Company’s significant accounting policies as described in the Form 10-K, except as described below. Leases At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits. The Company’s products are distributed in the U.S. through authorized specialty distributors and select wholesalers (collectively, customers) that resell its products to hospitals, the end users. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales: U.S. Net Product Sales Accounts Receivable Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 As of September 30, 2019 Customer A 32 % 32 % 27 % Customer B 38 % 34 % 35 % Customer C 30 % 30 % 38 % Total 100 % 96 % 100 % Revenue Recognition The Company adopted the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“ASC 606”) at the time of its first commercial shipment of GIAPREZA in the first quarter of 2018. The Company had no revenue from product sales prior to the first quarter of 2018. There have been no contract assets or liabilities recorded to date relating to product revenue. Under ASC 606, the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: • Chargebacks - Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers. • Discounts - The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers. • Returns - The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience and a review of comparable companies. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers. • Administrative Fees - The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. Net Loss per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock, stock options and warrants are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of September 30, 2019 and 2018 , there were 13.7 million and 14.3 million potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. Recent Accounting Pronouncements In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting (“ASU 2018-07”). The standard expands the scope of Accounting Standards Codification (“ASC”) Topic 718 to include share-based payment awards granted to nonemployees in exchange for goods and services. ASU 2018-07 is effective for annual and interim reporting periods beginning after December 15, 2018. In the first quarter 2019, the Company adopted ASU 2018-07. Prior to the adoption of ASU 2018-07, share-based payments awards granted to nonemployees were measured at fair value on their grant date, subject to periodic remeasurement, and share-based compensation expense was recognized on a straight-line basis over their vesting terms. After the adoption of ASU 2018-07, the fair value of share-based payment awards granted to nonemployees is not required to be remeasured periodically and share-based compensation expense will continue to be recorded on a straight-line basis over their vesting period, consistent with share-based payment awards granted to employees. As a result of the adoption of ASU 2018-07, the Company remeasured all of its outstanding nonemployee share-based payment awards at fair value and recognized a cumulative-effect adjustment of $0.2 million to accumulated deficit as of January 1, 2019. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). This guidance requires lessees to recognize operating leases with a term greater than one year on the balance sheet as a right-of-use asset and corresponding lease liability. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Although ASU 2016-02 is required to be adopted at the earliest period presented using a modified retrospective approach, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which allows for an alternative transition method of adoption by recognizing a cumulative-effect adjustment, if any, to the opening balance of retained earnings in the period of adoption. The Company adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed under ASU 2018-11. As a result, the Company recorded a lease liability and right-of-use lease asset of $31.8 million and $16.8 million , respectively, on its balance sheet as of January 1, 2019. The lease liability represents the present value of the remaining lease payments of the Company’s corporate headquarters lease (see Note 4), discounted using the Company’s incremental borrowing rate as of January 1, 2019. The corresponding right-of-use lease asset is recorded based on the lease liability, adjusted for the unamortized lease incentives received and the cumulative difference between rent expense and amounts paid under the corporate headquarters lease. The adoption of ASU 2016-02 did not have a material impact on either the statement of operations or statement of cash flows for the three and nine months ended September 30, 2019 .

Business

Business	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	Business La Jolla Pharmaceutical Company (collectively with its wholly-owned subsidiaries, the “Company”) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla’s investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin) is La Jolla's investigational product for the potential treatment of conditions characterized by iron overload. LJPC-401 is being investigated in a pivotal study in beta thalassemia patients with iron overload and in a Phase 2 study in patients with hereditary hemochromatosis. As of September 30, 2019 , the Company had $104.8 million in cash, compared to $172.6 million in cash as of December 31, 2018 . Based on the Company’s current operating plans and projections, the Company expects that its existing cash will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”).

Balance Sheet Account Details

Balance Sheet Account Details	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Details	Balance Sheet Details Restricted Cash Restricted cash as of September 30, 2019 and December 31, 2018 represents a standby letter of credit for the Company’s building lease in lieu of a security deposit during the term of such lease (see Note 4). There is a requirement to maintain $0.9 million of cash collateral in an account pledged as security for such letter of credit. Inventory, Net Inventory, net consisted of the following (in thousands): September 30, December 31, Work-in-process $ 1,129 $ 1,907 Finished goods 781 113 Total inventory, net $ 1,910 $ 2,020 As of September 30, 2019 and December 31, 2018 , total inventory is recorded net of $0.1 million and $0.8 million , respectively, of inventory reserves. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, December 31, Accrued interest expense $ 3,458 $ 2,260 Accrued clinical study costs 2,793 2,430 Accrued manufacturing costs 1,685 1,823 Accrued other 1,415 1,972 Total accrued expenses $ 9,351 $ 8,485

Company-wide Realignment (Notes

Company-wide Realignment (Notes)	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Company-wide Realignment	Company-wide Realignment On October 18, 2018, the Company effected a Company-wide realignment to increase its efficiency and focus on achieving its corporate goals. For the year ended December 31, 2018, total expense for these activities was $4.0 million , with $1.6 million included in research and development expense and $2.4 million included in selling, general and administrative expense. Total expense was comprised of $7.7 million for severance costs, offset by a $3.7 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of March 31, 2019, all severance costs had been paid. No expense for these activities was recorded during the three and nine months ended September 30, 2019 .

Leases Leases

Leases Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Leases On December 29, 2016, the Company entered into an agreement with BMR-Axiom LP to lease office and laboratory space as its corporate headquarters located at 4550 Towne Centre Court, San Diego, California (the “Lease”) for a period of 10 years commencing on October 30, 2017. The Company has an option to extend the Lease for an additional 5 years at the end of the initial term. The Company provided a standby letter of credit for $0.9 million in lieu of a security deposit. This amount will decrease to $0.6 million after year two of the lease term and decrease to $0.3 million after year 5 of the lease term. The annual rent under the Lease is subject to escalation during the term. In addition to rent, the Lease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises. The Lease contains customary default provisions, representations, warranties and covenants. The Lease is classified as an operating lease. Future minimum lease payments under the Lease as of September 30, 2019 are as follows (in thousands): 2019 $ 1,000 2020 4,058 2021 4,174 2022 4,294 2023 4,417 Thereafter 18,134 Total future minimum lease payments 36,077 Less: discount (6,173 ) Total lease liability $ 29,904 The Company recorded a lease liability for the Lease based on the present value of the Lease payments over the expected Lease term, discounted using the Company’s incremental borrowing rate. The Company recorded a corresponding right-of-use lease asset based on the lease liability, adjusted for incentives received prior to the Lease commencement date. The option to extend the Lease was not recognized as a part of either the Company’s lease liability or right-of-use lease asset. Lease expense for each of the three and nine months ended September 30, 2019 and 2018 was $0.7 million and $2.1 million , respectively. Amortization for the right-of-use lease asset was $0.4 million and $1.0 million for the three and nine months ended September 30, 2019 , respectively.

Deferred Royalty Obligation

Deferred Royalty Obligation	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Deferred Royalty Obligation	Deferred Royalty Obligation On May 10, 2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, the Company received $125.0 million in exchange for tiered royalty payments on worldwide net product sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net product sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10% . Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of 180% of the $125.0 million received by the Company. The Royalty Agreement expires when the maximum aggregate royalty payments have been made or on January 1, 2031, whichever comes first. The Royalty Agreement was entered into by the Company’s wholly-owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA. On receipt of the $125.0 million payment from HCR, the Company recorded a deferred royalty obligation of $125.0 million , net of issuance costs of $0.7 million . For the three months ended September 30, 2019 and 2018 , the Company recognized interest expense, including amortization of the obligation discount, of $2.8 million and $3.0 million , respectively. For the nine months ended September 30, 2019 and 2018 , the Company recognized interest expense, including amortization of the obligation discount, of $8.4 million and $4.6 million , respectively. The carrying value of the deferred royalty obligation as of September 30, 2019 was $124.4 million , net of unamortized obligation discount of $0.6 million , and was classified as noncurrent. The related interest expense liability was $13.7 million and $6.8 million as of September 30, 2019 and December 31, 2018 , respectively, of which $10.2 million and $4.5 million was classified as other noncurrent liabilities, respectively. During the three and nine months ended September 30, 2019 , the Company made royalty payments to HCR of $0.6 million and $1.4 million , respectively, and, as of September 30, 2019 , the Company recorded royalty obligations payable of $0.6 million in accrued expenses. The deferred royalty obligation is classified as Level 3 in the ASC 820-10, Fair Value Measurements and Disclosures, three-tier fair value hierarchy, and its carrying value approximates fair value. In the event of certain material breaches of the Royalty Agreement, HCR would have the right to terminate the Royalty Agreement and demand payment of an amount equal to either $125.0 million , minus aggregate royalties paid to HCR, or $225.0 million , minus aggregate royalties paid to HCR, depending on the type of breach. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the Company determined that the fair value of the embedded derivatives is immaterial as of September 30, 2019 . Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of operations.

Stockholders' Equity Stockholde

Stockholders' Equity Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity	Shareholders’ (Deficit) Equity 2018 Common Stock Offering In March 2018, the Company offered and sold 3,910,000 shares of common stock in an underwritten public offering at a price of $29.50 per share for gross proceeds of approximately $115.3 million . The Company received proceeds of approximately $109.8 million , net of approximately $5.5 million in underwriting commissions, discounts and other issuance costs. Preferred Stock In January 2019, the Company issued 782,031 shares of common stock upon the conversion of 2,737 shares of Series F Convertible Preferred Stock. As of September 30, 2019 , there were no shares of Series F Convertible Preferred Stock issued and outstanding. Warrants In March 2018, the Company issued 43,056 shares of common stock in a cashless exercise of 83,013 warrants to a third-party warrant holder. As of September 30, 2019 , the Company had outstanding warrants to purchase 10,000 shares of common stock.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Incentive Plans	Equity Incentive Plans 2013 Equity Incentive Plan A total of 8,100,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of September 30, 2019 , 941,077 shares of common stock remained available for future grants under the 2013 Equity Plan. 2018 Employee Stock Purchase Plan A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of September 30, 2019 , 611,599 shares of common stock remained available for future grants under the ESPP. Equity Awards The activity related to equity awards, which are comprised of stock options and inducement grants, during the nine months ended September 30, 2019 is summarized as follows: Equity Awards Weighted- average Exercise Price per Share Outstanding at December 31, 2018 6,466,214 $ 23.26 Granted (1) 1,982,402 $ 6.43 Cancelled/forfeited (1,503,029 ) $ 20.62 Outstanding at September 30, 2019 6,945,587 $ 19.03 (1) In March 2019, the Company issued a stock option grant to the Company’s recently appointed Chief Commercial Officer to purchase 80,000 shares of common stock at an exercise price equal to the fair market value of the Company’s common stock on the grant date. The grant was awarded as an inducement grant outside of the 2013 Equity Plan. On the first anniversary of the grant date, 25% of the underlying shares become exercisable with the remaining shares vesting on a monthly basis over the subsequent three years, subject to continued service during that time. Share-based Compensation Expense The classification of share-based compensation expense is summarized as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development $ 4,169 $ 5,895 $ 12,062 $ 16,992 Selling, general and administrative 2,250 3,985 7,460 12,134 Total share-based compensation expense $ 6,419 $ 9,880 $ 19,522 $ 29,126 As of September 30, 2019 , total unrecognized share-based compensation expense related to unvested equity awards was $41.0 million , which is expected to be recognized over a weighted-average period of 2.4 years. As of September 30, 2019 , there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation and Use of Estimates The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of SEC Regulation S-X. Accordingly, they should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 , filed with the SEC on March 4, 2019 (the “Form 10-K”).
Principles of Consolidation	The accompanying unaudited condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated balance sheet as of September 30, 2019 , the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 , the condensed consolidated statement of shareholders' (deficit) equity for the three and nine ended September 30, 2019 and the condensed consolidated statement of cash flows for the nine months ended September 30, 2019 .
Use of Estimates	The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ equity or cash flows. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated balance sheet as of December 31, 2018 contained in the Form 10-K.
Leases	Leases At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits.
Revenue Recognition	The Company adopted the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“ASC 606”) at the time of its first commercial shipment of GIAPREZA in the first quarter of 2018. The Company had no revenue from product sales prior to the first quarter of 2018. There have been no contract assets or liabilities recorded to date relating to product revenue. Under ASC 606, the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: • Chargebacks - Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers. • Discounts - The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers. • Returns - The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience and a review of comparable companies. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers. • Administrative Fees - The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock, stock options and warrants are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting (“ASU 2018-07”). The standard expands the scope of Accounting Standards Codification (“ASC”) Topic 718 to include share-based payment awards granted to nonemployees in exchange for goods and services. ASU 2018-07 is effective for annual and interim reporting periods beginning after December 15, 2018. In the first quarter 2019, the Company adopted ASU 2018-07. Prior to the adoption of ASU 2018-07, share-based payments awards granted to nonemployees were measured at fair value on their grant date, subject to periodic remeasurement, and share-based compensation expense was recognized on a straight-line basis over their vesting terms. After the adoption of ASU 2018-07, the fair value of share-based payment awards granted to nonemployees is not required to be remeasured periodically and share-based compensation expense will continue to be recorded on a straight-line basis over their vesting period, consistent with share-based payment awards granted to employees. As a result of the adoption of ASU 2018-07, the Company remeasured all of its outstanding nonemployee share-based payment awards at fair value and recognized a cumulative-effect adjustment of $0.2 million to accumulated deficit as of January 1, 2019. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). This guidance requires lessees to recognize operating leases with a term greater than one year on the balance sheet as a right-of-use asset and corresponding lease liability. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Although ASU 2016-02 is required to be adopted at the earliest period presented using a modified retrospective approach, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which allows for an alternative transition method of adoption by recognizing a cumulative-effect adjustment, if any, to the opening balance of retained earnings in the period of adoption. The Company adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed under ASU 2018-11. As a result, the Company recorded a lease liability and right-of-use lease asset of $31.8 million and $16.8 million , respectively, on its balance sheet as of January 1, 2019. The lease liability represents the present value of the remaining lease payments of the Company’s corporate headquarters lease (see Note 4), discounted using the Company’s incremental borrowing rate as of January 1, 2019. The corresponding right-of-use lease asset is recorded based on the lease liability, adjusted for the unamortized lease incentives received and the cumulative difference between rent expense and amounts paid under the corporate headquarters lease. The adoption of ASU 2016-02 did not have a material impact on either the statement of operations or statement of cash flows for the three and nine months ended September 30, 2019 .

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedules of Concentration of Risk	The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales: U.S. Net Product Sales Accounts Receivable Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 As of September 30, 2019 Customer A 32 % 32 % 27 % Customer B 38 % 34 % 35 % Customer C 30 % 30 % 38 % Total 100 % 96 % 100 %

Balance Sheet Account Details (

Balance Sheet Account Details (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory, net consisted of the following (in thousands): September 30, December 31, Work-in-process $ 1,129 $ 1,907 Finished goods 781 113 Total inventory, net $ 1,910 $ 2,020
Accrued Expenses	Accrued expenses consisted of the following (in thousands): September 30, December 31, Accrued interest expense $ 3,458 $ 2,260 Accrued clinical study costs 2,793 2,430 Accrued manufacturing costs 1,685 1,823 Accrued other 1,415 1,972 Total accrued expenses $ 9,351 $ 8,485

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity	Future minimum lease payments under the Lease as of September 30, 2019 are as follows (in thousands): 2019 $ 1,000 2020 4,058 2021 4,174 2022 4,294 2023 4,417 Thereafter 18,134 Total future minimum lease payments 36,077 Less: discount (6,173 ) Total lease liability $ 29,904

Equity Incentive Plans Equity I

Equity Incentive Plans Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity award activity	The activity related to equity awards, which are comprised of stock options and inducement grants, during the nine months ended September 30, 2019 is summarized as follows: Equity Awards Weighted- average Exercise Price per Share Outstanding at December 31, 2018 6,466,214 $ 23.26 Granted (1) 1,982,402 $ 6.43 Cancelled/forfeited (1,503,029 ) $ 20.62 Outstanding at September 30, 2019 6,945,587 $ 19.03 (1) In March 2019, the Company issued a stock option grant to the Company’s recently appointed Chief Commercial Officer to purchase 80,000 shares of common stock at an exercise price equal to the fair market value of the Company’s common stock on the grant date. The grant was awarded as an inducement grant outside of the 2013 Equity Plan. On the first anniversary of the grant date, 25% of the underlying shares become exercisable with the remaining shares vesting on a monthly basis over the subsequent three years, subject to continued service during that time.
Share-based compensation expense	The classification of share-based compensation expense is summarized as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development $ 4,169 $ 5,895 $ 12,062 $ 16,992 Selling, general and administrative 2,250 3,985 7,460 12,134 Total share-based compensation expense $ 6,419 $ 9,880 $ 19,522 $ 29,126

Business (Narrative) (Details)

Business (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 104,768	$ 172,604	$ 204,337

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Schedule of Concentration Risk) (Details)	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2019
Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		100.00%	96.00%
Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	100.00%
Customer A | Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		32.00%	32.00%
Customer A | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	27.00%
Customer B | Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		38.00%	34.00%
Customer B | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	35.00%
Customer C | Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk		30.00%	30.00%
Customer C | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk	38.00%

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands, shares in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants (in shares)	13.7	14.3
Cumulative effect adjustment to accumulated deficit	$ (160)	$ 0
Total lease liability	29,904
Right-of-use lease asset	$ 15,829
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total lease liability			$ 31,800
Right-of-use lease asset			16,800
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to accumulated deficit			160
Retained Earnings | Accounting Standards Update 2018-07
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to accumulated deficit			$ 200

Balance Sheet Account Details

Balance Sheet Account Details (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]
Inventory reserves	$ 0.1	$ 0.8
4550 Towne Centre Court, San Diego, California | Financial Standby Letter of Credit | Letter of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Cash collateral as security	$ 0.9

Balance Sheet Account Details_2

Balance Sheet Account Details (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Work-in-process	$ 1,129	$ 1,907
Finished goods	781	113
Total inventory, net	$ 1,910	$ 2,020

Balance Sheet Account Details_3

Balance Sheet Account Details (Summary of Accrued Expenses) (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued clinical study costs	$ 2,793	$ 2,430
Income Tax Examination, Interest Accrued	3,458	2,260
Accrued manufacturing costs	1,685	1,823
Accrued other	1,415	1,972
Total accrued expenses	$ 9,351	$ 8,485

Restructuring (Details)

Restructuring (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 0	$ 4,000,000
Reversal of non-cash-stock-based compensation expense		3,700,000
Research and development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		1,600,000
Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		2,400,000
Employee Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 7,700,000

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 30, 2022	Oct. 30, 2019	Dec. 29, 2016
Lessee, Lease, Description [Line Items]
Term of lease contract							10 years
Renewal term of lease contract							5 years
Lease expense	$ 0.7	$ 0.7	$ 2.1	$ 2.1
Right of use asset amortization	0.4		1
Standby Letters of Credit
Lessee, Lease, Description [Line Items]
Security deposit							$ 0.9
Forecast | Standby Letters of Credit
Lessee, Lease, Description [Line Items]
Security deposit					$ 0.3	$ 0.6
4550 Towne Centre Court, San Diego, California | Financial Standby Letter of Credit | Letter of Credit
Lessee, Lease, Description [Line Items]
Cash collateral as security	$ 0.9		$ 0.9

Leases (Lease liability maturit

Leases (Lease liability maturity) (Details) $ in Thousands	Sep. 30, 2019USD ($)
Leases [Abstract]
2019	$ 1,000
2020	4,058
2021	4,174
2022	4,294
2023	4,417
Thereafter	18,134
Total future minimum lease payments	36,077
Less: discount	(6,173)
Total lease liability	$ 29,904

Deferred Royalty Obligation (De

Deferred Royalty Obligation (Details) - USD ($)	May 10, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Debt Instrument [Line Items]
Deferred royalty obligation, net		$ 124,366,000		$ 124,366,000		$ 124,323,000
Royalty Obligation Payable		600,000		600,000
HealthCare Royalty Partners
Debt Instrument [Line Items]
Proceeds from royalty agreement	$ 125,000,000
Maximum potential royalty payout	180.00%
Required payment for breach of agreement, payment one	$ 125,000,000
Required payment for breach of agreement, payment two	225,000,000
HealthCare Royalty Partners | Loans Payable | Royalty Financing Agreement
Debt Instrument [Line Items]
Deferred royalty obligation, net	125,000,000	124,400,000		124,400,000
Debt issuance costs	$ 700,000
Interest expense		2,800,000	$ 3,000,000	8,400,000	$ 4,600,000
Unamortized debt discount		600,000		600,000
Accrued interest expense		13,700,000		13,700,000		6,800,000
Royalty payments		600,000		1,400,000
HealthCare Royalty Partners | Period One
Debt Instrument [Line Items]
Maximum potential royalty payout	10.00%
HealthCare Royalty Partners | Period Two
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%
HealthCare Royalty Partners | Payout Period
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%
Other Noncurrent Liabilities | HealthCare Royalty Partners | Loans Payable | Royalty Financing Agreement
Debt Instrument [Line Items]
Accrued interest expense		$ 10,200,000		$ 10,200,000		$ 4,500,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2019	Jan. 31, 2019	Dec. 31, 2018
Common Stock [Member]
Class of Stock [Line Items]
Shares issued upon conversion (in share)					782,031
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)				0	2,737	2,737
Underwriting Agreement [Member]
Class of Stock [Line Items]
Number of shares of common stock issued (in shares)	3,910,000
Price per share (usd per share)				$ 29.50
Proceeds from sale of stock	$ 115.3
Proceeds, net of underwriting commissions	109.8
Sale of stock issuance costs	$ 5.5
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during period (in shares)	43,056	782,000	3,910,000
Warrants exercised during period (in shares)	83,013
Warrants outstanding (in shares)				10,000

Equity Incentive Plans (Narrati

Equity Incentive Plans (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Jul. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized share-based compensation expense	$ 41
Recognized weighted average period	2 years 3 months 70 days
2013 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			8,100,000
Shares available for grant (in shares)	941,077
2018 Employee Stock Purchase Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	611,599	750,000

Equity Incentive Plans (Stock O

Equity Incentive Plans (Stock Option Activity) (Details) - $ / shares	1 Months Ended	9 Months Ended
	Mar. 31, 2019	Sep. 30, 2019
Shares Underlying Stock Options
Outstanding beginning balance, Shares underlying stock options and restricted stock awards (in shares)		6,466,214
Granted, Shares underlying stock options and restricted stock awards (in shares)		1,982,402
Forfeited, Shares underlying stock options and restricted stock awards (in shares)		(1,503,029)
Outstanding ending balance, Shares underlying stock options and restricted stock awards (in shares)		6,945,587
Weighted- Average Exercise Price per Share
Outstanding beginning balance, Weighted - average exercise price (usd per share)		$ 23.26
Granted, Weighted - average exercise price (usd per share)		6.43
Forfeited, Weighted - average exercise price (usd per share)		20.62
Outstanding ending balance, Weighted - average exercise price (usd per share)		$ 19.03
Chief Commercial Officer [Member]
Shares Underlying Stock Options
Granted, Shares underlying stock options and restricted stock awards (in shares)	80,000
Employee Stock Option [Member] | Chief Commercial Officer [Member]
Weighted- Average Exercise Price per Share
Options vesting percentage	25.00%
Award vesting period	3 years

Equity Incentive Plans (Share-b

Equity Incentive Plans (Share-based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 6,419	$ 9,880	$ 19,522	$ 29,126
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	4,169	5,895	12,062	16,992
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 2,250	$ 3,985
General and Administrative Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense			$ 7,460	$ 12,134

Uncategorized Items - ljpc-2019

Label	Element	Value
Restricted Cash	us-gaap_RestrictedCash	$ 909,000
Restricted Cash	us-gaap_RestrictedCash	909,000
Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (160,000)